Avidity Biosciences, Inc. (RNAM)

Avidity Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-684.63	-322.3	-212.22	-174	-118.01
Depreciation & Amortization	4.15	2.78	2.1	1.39	0.64
Loss (Gain) From Sale of Assets	0.14	-	-	-	-
Loss (Gain) From Sale of Investments	-12.52	-21.45	-11.27	-0.62	0.18
Stock-Based Compensation	97.84	51.36	38.22	27.14	17.06
Other Operating Activities	4.24	3.3	2.98	2.75	0.68
Change in Accounts Payable	3.8	-0.35	4.17	18.32	6.04
Change in Unearned Revenue	-8.62	-10.32	62.99	-5.12	-4.44
Change in Other Net Operating Assets	-54.84	-3.89	-6.03	-6.13	3.04
Operating Cash Flow	-650.44	-300.87	-119.06	-136.27	-94.81
Capital Expenditures	-13.32	-7.07	-4.23	-2.82	-3.74
Investment in Securities	-20.65	-847.14	-125.84	-187.13	-78.78
Other Investing Activities	-4.07	-	-	-	-
Investing Cash Flow	-38.04	-854.2	-130.07	-189.96	-82.52
Issuance of Common Stock	863.4	1,051	93.86	346.17	176.32
Repurchase of Common Stock	-12.41	-	-	-	-
Other Financing Activities	-	141.4	-	-	-
Financing Cash Flow	850.99	1,192	93.86	346.17	176.32
Foreign Exchange Rate Adjustments	0.14	-	-	-	-
Net Cash Flow	162.65	37.29	-155.27	19.95	-1.01
Free Cash Flow	-663.76	-307.94	-123.29	-139.09	-98.55
Free Cash Flow Margin	-3539.11%	-2825.88%	-1289.66%	-1507.92%	-1056.76%
Free Cash Flow Per Share	-4.82	-2.76	-1.69	-2.67	-2.38
Levered Free Cash Flow	-341.02	-197.47	-86.66	-71.82	-48.59
Unlevered Free Cash Flow	-341.02	-197.47	-86.66	-71.82	-48.59
Change in Working Capital	-59.66	-14.56	61.13	7.07	4.64

Source: S&P Global Market Intelligence. Standard template. Financial Sources.